BioSig Technologies, Inc. (NASDAQ:BSGM – Get Rating) insider Gray Fleming bought 36,036 shares of the company’s stock in a transaction on Wednesday, August 24th. The stock was bought at an average cost of $1.18 per share, with a total value of $42,522.48. Following the completion of the acquisition, the insider now owns 36,036 shares of the company’s stock, valued at approximately $42,522.48. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
BioSig Technologies Stock Down 3.5 %
Shares of BioSig Technologies stock opened at $1.09 on Friday. BioSig Technologies, Inc. has a 12-month low of $0.50 and a 12-month high of $4.10. The company has a 50-day moving average of $0.76 and a two-hundred day moving average of $0.98.
BioSig Technologies (NASDAQ:BSGM – Get Rating) last issued its earnings results on Monday, August 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. BioSig Technologies had a negative net margin of 22,438.64% and a negative return on equity of 253.64%. As a group, equities research analysts forecast that BioSig Technologies, Inc. will post -0.64 earnings per share for the current year.
Institutional Inflows and Outflows
BioSig Technologies Company Profile
BioSig Technologies, Inc, together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time.
- Get a free copy of the StockNews.com research report on BioSig Technologies (BSGM)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.